Your browser doesn't support javascript.
loading
Two cases of dupilumab-responsive Kimura disease.
Battesti, Gilles; Jachiet, Marie; Lepelletier, Clémence; Petit, Antoine; Vignon-Pennamen, Marie-Dominique; Cassius, Charles; de Masson, Adèle; Battistella, Maxime; Bagot, Martine; Bouaziz, Jean David; Mahévas, Thibault.
Afiliação
  • Battesti G; Departments of Dermatology.
  • Jachiet M; Université Paris Cité, Paris, France.
  • Lepelletier C; Departments of Dermatology.
  • Petit A; Departments of Dermatology.
  • Vignon-Pennamen MD; Departments of Dermatology.
  • Cassius C; Pathology, Saint-Louis Hospital, Paris, France.
  • de Masson A; Departments of Dermatology.
  • Battistella M; Université Paris Cité, Paris, France.
  • Bagot M; Departments of Dermatology.
  • Bouaziz JD; Université Paris Cité, Paris, France.
  • Mahévas T; Université Paris Cité, Paris, France.
Clin Exp Dermatol ; 49(5): 502-506, 2024 Apr 23.
Article em En | MEDLINE | ID: mdl-38149974
ABSTRACT
Kimura disease (KD) is a rare, chronic angiolymphoproliferative inflammatory disease appearing to be mostly restricted to the skin and soft tissue. Cutaneous involvement of KD includes head and/or neck nodules showing suggestive histological features, frequently associated with an atopic dermatitis-like or prurigo-like presentation. KD is challenging to treat, with high rate of recurrence using current therapeutic strategies. Evidence for involvement of a T-helper type 2 (Th2) immune response in KD pathogenesis has been found in previous studies. Consequently, this study aimed to determine the efficacy and safety of dupilumab, a human monoclonal antibody that inhibits signalling of key Th2 cytokines, interleukin (IL)-4 and IL-13, within a single-centre cohort of patients with cutaneous KD. Two adults with a diagnosis of refractory (failure of at least one treatment line) cutaneous-restricted KD based on clinical, biological, histological, molecular and imaging findings received dupilumab for KD, and showed dramatic response with a good safety profile.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Monoclonais Humanizados / Doença de Kimura Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Monoclonais Humanizados / Doença de Kimura Idioma: En Ano de publicação: 2024 Tipo de documento: Article